Holen Sie sich die Stockscreener-App
3.33
3.20%
-0.11
Handel nachbörslich:
3.32
-0.01
-0.30%
Schlusskurs vom Vortag:
$3.44
Offen:
$3.4
24-Stunden-Volumen:
73,321
Relative Volume:
0.36
Marktkapitalisierung:
$7.40M
Einnahmen:
$895.50K
Nettoeinkommen (Verlust:
$-26.30M
KGV:
-2.0305
EPS:
-1.64
Netto-Cashflow:
$-23.84M
1W Leistung:
-16.08%
1M Leistung:
-34.32%
6M Leistung:
-67.53%
1J Leistung:
-92.29%
1-Tages-Spanne:
$3.14
$3.589
1-Wochen-Bereich:
$2.72
$3.9873
52-Wochen-Spanne:
$2.72
$45.20
Mainz Biomed N V Stock (MYNZ) Company Profile
Firmenname
Mainz Biomed N V
Sektor
Branche
Telefon
-
Adresse
-
Vergleichen Sie MYNZ mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MYNZ
Mainz Biomed N V
|
3.33 | 7.40M | 895.50K | -26.30M | -23.84M | -1.64 |
|
TMO
Thermo Fisher Scientific Inc
|
470.03 | 177.32B | 42.88B | 6.34B | 7.27B | 16.53 |
|
DHR
Danaher Corp
|
197.90 | 141.59B | 23.88B | 3.90B | 5.30B | 5.28 |
|
IDXX
Idexx Laboratories Inc
|
410.76 | 33.29B | 3.90B | 887.87M | 798.08M | 10.67 |
|
A
Agilent Technologies Inc
|
109.67 | 31.28B | 6.53B | 1.26B | 1.31B | 4.35 |
|
IQV
Iqvia Holdings Inc
|
167.69 | 29.57B | 15.41B | 1.37B | 2.11B | 7.50 |
Mainz Biomed N V Stock (MYNZ) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-02-14 | Eingeleitet | Maxim Group | Buy |
| 2024-11-25 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2023-11-21 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2022-06-21 | Eingeleitet | H.C. Wainwright | Buy |
Mainz Biomed N V Aktie (MYNZ) Neueste Nachrichten
Mainz BioMed's Trial To Bring Critical Early Cancer Detection One Step Closer - Benzinga
Mainz Biomed Reports 2024 Financial Results and Provides Corporate Update - GlobeNewswire
Mainz Biomed Reports 2024 Financial Success and Strategic Advances - TipRanks
Mainz Biomed Reports 2024 Financial Results and Provides Corporate Update - GlobeNewswire Inc.
Virtu Financial LLC Takes $79,000 Position in Mainz Biomed (NASDAQ:MYNZ) - Defense World
Mainz Biomed (MYNZ) Expected to Announce Quarterly Earnings on Tuesday - Defense World
Mainz Biomed begins pivotal colorectal cancer test study By Investing.com - Investing.com Canada
Mainz Biomed Enrolls First Patient In EAArly DETECT 2 Study To Advance Colorectal Cancer Test - Nasdaq
Mainz Biomed begins pivotal colorectal cancer test study - Investing.com
Mainz Biomed Enrolls First Patient in Its eAArly DETECT 2 Clinical Study - GlobeNewswire
Revolutionary AI-Powered Cancer Test: Mainz Biomed Begins Major Clinical Trial - Stock Titan
(MYNZ) Proactive Strategies - Stock Traders Daily
Mainz Biomed secures license for pancreatic cancer test By Investing.com - Investing.com Australia
Mainz Biomed Licenses MRNA Biomarkers For Non-Invasive Pancreatic Cancer Screening Test - Nasdaq
Mainz Biomed, Liquid Biosciences Partner on Blood-Based Test for Pancreatic Cancer - Marketscreener.com
Mainz Biomed’s Breakthrough in Pancreatic Cancer Detection - TipRanks
Mainz Biomed secures license for pancreatic cancer test - Investing.com India
Mainz Biomed and Liquid Biosciences Make Groundbreaking Discovery of mRNA Biomarkers for Blood Based Detection of Pancreatic Cancer - The Manila Times
Mainz Biomed Signs Exclusive Licensing Agreement with Liquid Biosciences for Novel mRNA Biomarkers in Pancreatic Cancer Detection - Nasdaq
Mainz Biomed and Liquid Biosciences Make Groundbreaking - GlobeNewswire
Mainz Biomed and Liquid Biosciences Make Groundbreaking Discovery of mRNA Biomarkers for Blood ... - The Bakersfield Californian
Colorectal Cancer Awareness Month: Mainz Biomed Advocates for a Shift from Screening to Prevention - GlobeNewswire
Can Mainz Biomed's 82% Detection Rate Technology Revolutionize Colorectal Cancer Prevention? - StockTitan
(MYNZ) Trading Advice - Stock Traders Daily
Mainz Biomed Expands into Switzerland with labor team w - GlobeNewswire
Mainz Biomed Partners with labor team w ag to Launch ColoAlert® Colorectal Cancer Screening Test in Switzerland - Nasdaq
First DNA-Based Cancer Test Enters Swiss Market: Can Mainz Biomed Transform Screening? - StockTitan
Mainz Biomed (NASDAQ:MYNZ) Coverage Initiated at Maxim Group - Defense World
Maxim Group Initiates Coverage of Mainz Biomed N.V. (MYNZ) with Buy Recommendation - Nasdaq
This Analog Devices Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday - Benzinga
How To Trade (MYNZ) - Stock Traders Daily
Mainz Biomed and GANZIMMUN Announce Launch of Enhanced - GlobeNewswire
Mainz Biomed Collaborates with GANZIMMUN Diagnostics to Launch Enhanced ColoAlert Colorectal Cancer Screening Test in Germany - Nasdaq
Mainz Biomed's Revolutionary DNA Tech Powers New German Cancer ScreeningWhat Sets It Apart - StockTitan
A stock that deserves closer examination: Mainz Biomed N.V (MYNZ) - US Post News
The Future of Mainz Biomed N.V: Analyzing MYNZ - The InvestChronicle
Mainz Biomed regains Nasdaq compliance with equity rule By Investing.com - Investing.com Canada
Mainz Biomed regains Nasdaq compliance with equity rule - MSN
Mainz Biomed Regains Nasdaq Listing Compliance - TipRanks
Mainz Biomed N.V. Regains Compliance with Nasdaq Capital Market Listing Requirements - GlobeNewswire
Mainz Biomed Achieves Full Nasdaq Compliance, Secures Market Position - StockTitan
Mainz Biomed Regains Compliance With Nasdaq Listing Rules - Nasdaq
Mainz Biomed (MYNZ) Stock Price, News & Analysis - MarketBeat
Mainz Biomed (NASDAQ:MYNZ) Shares Down 3.7% – What’s Next? - Defense World
Mainz Biomed Initiates U.S. Clinical Study to Evaluate - GlobeNewswire
Mainz Biomed Initiates U.S. Clinical Study to Evaluate Performance of Next Generation Test on - The Bakersfield Californian
Mainz Biomed Initiates U.S. Clinical Study to Evaluate Performance of Next Generation Test on Advanced Adenomas over Large Patient Population - Marketscreener.com
Mainz Biomed Moves Forward With Pivotal CRC Study After Feasibility Trial - Nasdaq
Mainz Biomed B.V. Addresses Nasdaq Listing Compliance Issue - TipRanks
Mainz Biomed (NASDAQ:MYNZ) Stock Price Down 5.3% – Here’s Why - Defense World
MYNZMainz Biomed N.V. Ordinary Shares Latest Stock News & Market Updates - StockTitan
Finanzdaten der Mainz Biomed N V-Aktie (MYNZ)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.14%
1.59%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):